Mg Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 28 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 711.38%
- Profit Growth 19691.23%
- Ebitda -652.82%
- Net Worth 24.27%
- Total Assets 7151.10%
About Mg Pharmaceuticals
Mg Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 December 1996 and has a history of 28 years and one month. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Swati Gupta and Manoj Gupta serve as directors at the Company.
Company Details
-
Location
Kolkata, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232WB1996PTC082177
-
Company No.
082177
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Dec 1996
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Mg Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Gupta
|
Director | 04-Dec-1996 | Current |
|
Swati Gupta
|
Director | 04-Dec-1996 | Current |
Financial Performance of Mg Pharmaceuticals.
Mg Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 711.38% increase. The company also saw a substantial improvement in profitability, with a 19691.23% increase in profit. The company's net worth Soared by an impressive increase of 24.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mg Pharmaceuticals?
In 2018, Mg Pharmaceuticals had a promoter holding of 95.00% and a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Tetradrip Pharma Private LimitedSwati Gupta and Manoj Gupta are mutual person
-
Pharma Impex Laboratories Pvt LtdSwati Gupta and Manoj Gupta are mutual person
-
Clinovation Research Private LimitedSwati Gupta and Manoj Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mg Pharmaceuticals?
Unlock and access historical data on people associated with Mg Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mg Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mg Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.